Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells

Identifieur interne : 002640 ( Main/Exploration ); précédent : 002639; suivant : 002641

Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells

Auteurs : Gerben A. Koning [Pays-Bas] ; Henriëtte W. M. Morselt [Pays-Bas] ; Maria J. Velinova [Pays-Bas] ; Jan Donga [Pays-Bas] ; Arko Gorter [Pays-Bas] ; Theresa M. Allen [Canada] ; Samuel Zalipsky [États-Unis] ; Jan A. A. M. Kamps [Pays-Bas] ; Gerrit L. Scherphof [Pays-Bas]

Source :

RBID : ISTEX:AD541D2CD638235C7A7901FE4CDC1EA6107D98AA

English descriptors

Abstract

Abstract: A monoclonal antibody against the rat colon carcinoma CC531 was covalently coupled to liposomes containing a dipalmitoylated derivative of the anticancer drug FUdR as a prodrug in their bilayers. We investigated the in vitro interaction of these liposomes with CC531 target cells and the mechanism by which they deliver the active drug FUdR intracellularly to the cells by monitoring the fate of the liposomal bilayer markers cholesterol-[14C]oleate and [3H]cholesteryloleylether as well as the 3H-labeled prodrug and colloidal gold as an encapsulated liposome marker. After binding of the immunoliposomes to the cell surface, only limited amounts were internalized as demonstrated by a low level of hydrolysis of liposomal cholesterol ester and by morphological studies employing colloidal gold-labeled immunoliposomes. By contrast, already within 24 h immunoliposome-incorporated FUdR-dP was hydrolyzed virtually completely to the parent drug FUdR intracellularly. This process was inhibited by a variety of endocytosis inhibitors, indicating that the prodrug enters and is processed by the cells by a mechanism involving an endocytic process, resulting in intracellular FUdR concentrations up to 3000-fold higher than those in the medium. Immunoliposomes containing poly(ethyleneglycol) (PEG) chains on their surface, with the antibody coupled either directly to the bilayer or at the distal end of the PEG chains were able to deliver the prodrug into the tumor cells at the same rate as immunoliposomes without PEG. Based on these observations, we tentatively conclude that during the interaction of the immunoliposomes with the tumor cells the lipophilic prodrug FUdR-dP is selectively transferred to the cell surface and subsequently internalized by constitutive endocytic or pinocytic invaginations of the plasma membrane, thus ultimately delivering the prodrug to a lysosomal compartment where hydrolysis and release of parent drug takes place. This concept allows for an efficient delivery of a liposome-associated drug without the need for the liposome as such to be internalized by the cells.

Url:
DOI: 10.1016/S0005-2736(99)00091-7


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells</title>
<author>
<name sortKey="Koning, Gerben A" sort="Koning, Gerben A" uniqKey="Koning G" first="Gerben A." last="Koning">Gerben A. Koning</name>
</author>
<author>
<name sortKey="Morselt, Henriette W M" sort="Morselt, Henriette W M" uniqKey="Morselt H" first="Henriëtte W. M." last="Morselt">Henriëtte W. M. Morselt</name>
</author>
<author>
<name sortKey="Velinova, Maria J" sort="Velinova, Maria J" uniqKey="Velinova M" first="Maria J." last="Velinova">Maria J. Velinova</name>
</author>
<author>
<name sortKey="Donga, Jan" sort="Donga, Jan" uniqKey="Donga J" first="Jan" last="Donga">Jan Donga</name>
</author>
<author>
<name sortKey="Gorter, Arko" sort="Gorter, Arko" uniqKey="Gorter A" first="Arko" last="Gorter">Arko Gorter</name>
</author>
<author>
<name sortKey="Allen, Theresa M" sort="Allen, Theresa M" uniqKey="Allen T" first="Theresa M." last="Allen">Theresa M. Allen</name>
</author>
<author>
<name sortKey="Zalipsky, Samuel" sort="Zalipsky, Samuel" uniqKey="Zalipsky S" first="Samuel" last="Zalipsky">Samuel Zalipsky</name>
</author>
<author>
<name sortKey="Kamps, Jan A A M" sort="Kamps, Jan A A M" uniqKey="Kamps J" first="Jan A. A. M." last="Kamps">Jan A. A. M. Kamps</name>
</author>
<author>
<name sortKey="Scherphof, Gerrit L" sort="Scherphof, Gerrit L" uniqKey="Scherphof G" first="Gerrit L." last="Scherphof">Gerrit L. Scherphof</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:AD541D2CD638235C7A7901FE4CDC1EA6107D98AA</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1016/S0005-2736(99)00091-7</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-TT763V6L-V/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002348</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002348</idno>
<idno type="wicri:Area/Istex/Curation">002348</idno>
<idno type="wicri:Area/Istex/Checkpoint">001456</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001456</idno>
<idno type="wicri:doubleKey">0005-2736:1999:Koning G:selective:transfer:of</idno>
<idno type="wicri:Area/Main/Merge">002676</idno>
<idno type="wicri:Area/Main/Curation">002640</idno>
<idno type="wicri:Area/Main/Exploration">002640</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells</title>
<author>
<name sortKey="Koning, Gerben A" sort="Koning, Gerben A" uniqKey="Koning G" first="Gerben A." last="Koning">Gerben A. Koning</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Physiological Chemistry, Groningen University Institute for Drug Exploration (GUIDE), Faculty of Medical Sciences, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen</wicri:regionArea>
<wicri:noRegion>9713 AV Groningen</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Morselt, Henriette W M" sort="Morselt, Henriette W M" uniqKey="Morselt H" first="Henriëtte W. M." last="Morselt">Henriëtte W. M. Morselt</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Physiological Chemistry, Groningen University Institute for Drug Exploration (GUIDE), Faculty of Medical Sciences, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen</wicri:regionArea>
<wicri:noRegion>9713 AV Groningen</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Velinova, Maria J" sort="Velinova, Maria J" uniqKey="Velinova M" first="Maria J." last="Velinova">Maria J. Velinova</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Physiological Chemistry, Groningen University Institute for Drug Exploration (GUIDE), Faculty of Medical Sciences, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen</wicri:regionArea>
<wicri:noRegion>9713 AV Groningen</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Donga, Jan" sort="Donga, Jan" uniqKey="Donga J" first="Jan" last="Donga">Jan Donga</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Cell Biology and Electron Microscopy, University of Groningen, Oostersingel 69, 9713 EZ Groningen</wicri:regionArea>
<orgName type="university">Université de Groningue</orgName>
<placeName>
<settlement type="city">Groningue (ville)</settlement>
<region>Groningue (province)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gorter, Arko" sort="Gorter, Arko" uniqKey="Gorter A" first="Arko" last="Gorter">Arko Gorter</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden</wicri:regionArea>
<wicri:noRegion>2300 RC Leiden</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Allen, Theresa M" sort="Allen, Theresa M" uniqKey="Allen T" first="Theresa M." last="Allen">Theresa M. Allen</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pharmacology, University of Alberta, Edmonton, AL T6G 2H7</wicri:regionArea>
<wicri:noRegion>AL T6G 2H7</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zalipsky, Samuel" sort="Zalipsky, Samuel" uniqKey="Zalipsky S" first="Samuel" last="Zalipsky">Samuel Zalipsky</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SEQUUS Pharmaceuticals Inc., 960 Hamilton Court, Menlo Park, CA 94025</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kamps, Jan A A M" sort="Kamps, Jan A A M" uniqKey="Kamps J" first="Jan A. A. M." last="Kamps">Jan A. A. M. Kamps</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Physiological Chemistry, Groningen University Institute for Drug Exploration (GUIDE), Faculty of Medical Sciences, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen</wicri:regionArea>
<wicri:noRegion>9713 AV Groningen</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Scherphof, Gerrit L" sort="Scherphof, Gerrit L" uniqKey="Scherphof G" first="Gerrit L." last="Scherphof">Gerrit L. Scherphof</name>
<affiliation wicri:level="1">
<country wicri:rule="url">Pays-Bas</country>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Physiological Chemistry, Groningen University Institute for Drug Exploration (GUIDE), Faculty of Medical Sciences, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen</wicri:regionArea>
<wicri:noRegion>9713 AV Groningen</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">BBA - Biomembranes</title>
<title level="j" type="abbrev">BBAMEM</title>
<idno type="ISSN">0005-2736</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1999">1999</date>
<biblScope unit="volume">1420</biblScope>
<biblScope unit="issue">1–2</biblScope>
<biblScope unit="page" from="153">153</biblScope>
<biblScope unit="page" to="167">167</biblScope>
</imprint>
<idno type="ISSN">0005-2736</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0005-2736</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>(Colon cancer cell)</term>
<term>5-Fluorodeoxyuridine</term>
<term>CC52, colon carcinoma CC531-specific antibody</term>
<term>Chol, cholesterol</term>
<term>Drug delivery</term>
<term>FCS, fetal calf serum</term>
<term>FUdR, 5-fluoro-2′-deoxyuridine</term>
<term>FUdR-dP, 3′,5′-O-dipalmitoyl-FUdR</term>
<term>Hz-PEG-DSPE, hydrazide-PEG-distearoylphosphatidylethanolamine</term>
<term>Immunoliposome</term>
<term>Lipophilic prodrug</term>
<term>MPB-PE, maleimido-4-(p-phenylbutyryl)phosphatidylethanolamine</term>
<term>PC, phosphatidylcholine</term>
<term>PEG, methoxy-poly(ethyleneglycol)2000-distearoylphosphatidylethanolamine</term>
<term>Selective transfer</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Acta</term>
<term>Antibody solution</term>
<term>Average diameter</term>
<term>Bbamem</term>
<term>Bilayer</term>
<term>Biochim</term>
<term>Biochimica</term>
<term>Biophys</term>
<term>Biophysica</term>
<term>Biophysica acta</term>
<term>Borssum waalkes</term>
<term>Carcinoma</term>
<term>Cell pellet</term>
<term>Cell surface</term>
<term>Cellular protein</term>
<term>Chloroform</term>
<term>Cholesterol ester</term>
<term>Colloidal</term>
<term>Colloidal gold</term>
<term>Colloidal immunoliposomes</term>
<term>Colon</term>
<term>Colon cancer cells</term>
<term>Degradation</term>
<term>Electron microscopy</term>
<term>Encapsulated marker</term>
<term>Ester</term>
<term>Free fudr</term>
<term>Fudr</term>
<term>Hydrolysis</term>
<term>Immunoliposomal</term>
<term>Immunoliposomes</term>
<term>Incubation</term>
<term>Incubation medium</term>
<term>Incubation period</term>
<term>Incubation time</term>
<term>Inhibitor</term>
<term>Internalization</term>
<term>Intracellular</term>
<term>Intracellular fudr</term>
<term>Intracellularly</term>
<term>Intralysosomal</term>
<term>Intralysosomal degradation</term>
<term>Koning</term>
<term>Lipid</term>
<term>Lipophilic</term>
<term>Lipophilic prodrug</term>
<term>Liposomal</term>
<term>Liposomal bilayer</term>
<term>Liposomal cholesterol ester</term>
<term>Liposome</term>
<term>Metabolic fate</term>
<term>Monoclonal antibody</term>
<term>Morphological studies</term>
<term>Nmol</term>
<term>Plasma membrane</term>
<term>Prodrug</term>
<term>Scherphof</term>
<term>Trypsin</term>
<term>Trypsin treatment</term>
<term>Tumor cells</term>
<term>Zalipsky</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: A monoclonal antibody against the rat colon carcinoma CC531 was covalently coupled to liposomes containing a dipalmitoylated derivative of the anticancer drug FUdR as a prodrug in their bilayers. We investigated the in vitro interaction of these liposomes with CC531 target cells and the mechanism by which they deliver the active drug FUdR intracellularly to the cells by monitoring the fate of the liposomal bilayer markers cholesterol-[14C]oleate and [3H]cholesteryloleylether as well as the 3H-labeled prodrug and colloidal gold as an encapsulated liposome marker. After binding of the immunoliposomes to the cell surface, only limited amounts were internalized as demonstrated by a low level of hydrolysis of liposomal cholesterol ester and by morphological studies employing colloidal gold-labeled immunoliposomes. By contrast, already within 24 h immunoliposome-incorporated FUdR-dP was hydrolyzed virtually completely to the parent drug FUdR intracellularly. This process was inhibited by a variety of endocytosis inhibitors, indicating that the prodrug enters and is processed by the cells by a mechanism involving an endocytic process, resulting in intracellular FUdR concentrations up to 3000-fold higher than those in the medium. Immunoliposomes containing poly(ethyleneglycol) (PEG) chains on their surface, with the antibody coupled either directly to the bilayer or at the distal end of the PEG chains were able to deliver the prodrug into the tumor cells at the same rate as immunoliposomes without PEG. Based on these observations, we tentatively conclude that during the interaction of the immunoliposomes with the tumor cells the lipophilic prodrug FUdR-dP is selectively transferred to the cell surface and subsequently internalized by constitutive endocytic or pinocytic invaginations of the plasma membrane, thus ultimately delivering the prodrug to a lysosomal compartment where hydrolysis and release of parent drug takes place. This concept allows for an efficient delivery of a liposome-associated drug without the need for the liposome as such to be internalized by the cells.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
<li>Pays-Bas</li>
<li>États-Unis</li>
</country>
<region>
<li>Californie</li>
<li>Groningue (province)</li>
</region>
<settlement>
<li>Groningue (ville)</li>
</settlement>
<orgName>
<li>Université de Groningue</li>
</orgName>
</list>
<tree>
<country name="Pays-Bas">
<noRegion>
<name sortKey="Koning, Gerben A" sort="Koning, Gerben A" uniqKey="Koning G" first="Gerben A." last="Koning">Gerben A. Koning</name>
</noRegion>
<name sortKey="Donga, Jan" sort="Donga, Jan" uniqKey="Donga J" first="Jan" last="Donga">Jan Donga</name>
<name sortKey="Gorter, Arko" sort="Gorter, Arko" uniqKey="Gorter A" first="Arko" last="Gorter">Arko Gorter</name>
<name sortKey="Kamps, Jan A A M" sort="Kamps, Jan A A M" uniqKey="Kamps J" first="Jan A. A. M." last="Kamps">Jan A. A. M. Kamps</name>
<name sortKey="Morselt, Henriette W M" sort="Morselt, Henriette W M" uniqKey="Morselt H" first="Henriëtte W. M." last="Morselt">Henriëtte W. M. Morselt</name>
<name sortKey="Scherphof, Gerrit L" sort="Scherphof, Gerrit L" uniqKey="Scherphof G" first="Gerrit L." last="Scherphof">Gerrit L. Scherphof</name>
<name sortKey="Scherphof, Gerrit L" sort="Scherphof, Gerrit L" uniqKey="Scherphof G" first="Gerrit L." last="Scherphof">Gerrit L. Scherphof</name>
<name sortKey="Velinova, Maria J" sort="Velinova, Maria J" uniqKey="Velinova M" first="Maria J." last="Velinova">Maria J. Velinova</name>
</country>
<country name="Canada">
<noRegion>
<name sortKey="Allen, Theresa M" sort="Allen, Theresa M" uniqKey="Allen T" first="Theresa M." last="Allen">Theresa M. Allen</name>
</noRegion>
</country>
<country name="États-Unis">
<region name="Californie">
<name sortKey="Zalipsky, Samuel" sort="Zalipsky, Samuel" uniqKey="Zalipsky S" first="Samuel" last="Zalipsky">Samuel Zalipsky</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002640 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002640 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:AD541D2CD638235C7A7901FE4CDC1EA6107D98AA
   |texte=   Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021